I have followed SLA pretty closely over the years.It has gone...

I have followed SLA pretty closely over the years.

It has gone from:

1) a stock with enormously committed management team tackling a Huge Project that nobody outside the company really believed in (share price 10-18cents), to

2) A company where enough people believed in the Huge Project for it to trade at a much higher level ($1.50, market cap $200m+), but with truly tangible evidence of the success of the venture (which really comes down to sales) always just out of reach, to

3) A dreadful mess where product commercialisation is essentially unproven and where an unwilling shareholder holds a HUGE percentage of the company.

We have seen Bioeffective B generate very little revenue despite the supposedly huge market that exists for sauna treatments, and Bioeffective A is a very slow build (but as of this week I am a customer - I bought two packs on online to kick off the winter flu season) . . . . therefore increasingly it is all about Ropren.

For the OPES stock to move within a reasonable timeframe, the ANZ needs to be able to find a buyer. . . . and given the size of the line this requires serious institutional interest.

AT present, there would be no interest. No meaningful insto has ever touched SLA to my knowledge and even the slicker retail money that has definitely been attracted to this stock at different times will be staying on sidelines for now.

The only thing that SLA can do to create a market for the confiscated stock is to make their corporate story investable for instos. This just MIGHT be achieved once the Ropren revenue starts rolling in. But why is there no revenue to date? why are the hospitals that were meant to be queuing up to buy ropren not yet taking the product? i had thought it was meant to be a done deal???

If SLA wants to solve its problems quickly, then Ropren revenue is the only answer.